CU20170109A7 - Derivado de quinoleina para tratar y prevenir infecciones virales - Google Patents
Derivado de quinoleina para tratar y prevenir infecciones viralesInfo
- Publication number
- CU20170109A7 CU20170109A7 CUP2017000109A CU20170109A CU20170109A7 CU 20170109 A7 CU20170109 A7 CU 20170109A7 CU P2017000109 A CUP2017000109 A CU P2017000109A CU 20170109 A CU20170109 A CU 20170109A CU 20170109 A7 CU20170109 A7 CU 20170109A7
- Authority
- CU
- Cuba
- Prior art keywords
- derivative
- quinoleine
- treat
- present
- viral infections
- Prior art date
Links
- XNMYNYSCEJBRPZ-UHFFFAOYSA-N 2-[(3-butyl-1-isoquinolinyl)oxy]-N,N-dimethylethanamine Chemical class C1=CC=C2C(OCCN(C)C)=NC(CCCC)=CC2=C1 XNMYNYSCEJBRPZ-UHFFFAOYSA-N 0.000 title abstract 3
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 3
- 208000030507 AIDS Diseases 0.000 abstract 2
- 206010038997 Retroviral infections Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
<p>La presente invención se refiere derivados de quinoleínas de la fórmula (1) y (4)</p> <p>ESPACIO PARA FÓRMULAS</p> <p>o una de sus sales farmacéuticamente aceptables. La presente invención se refiere además al derivado de quinoleína para el medicamento y para su uso en el tratamiento o prevención de una infección viral o retroviral y e particular el SIDA o una afección relacionada con el SIDA o el virus de inmunodeficiencia humana (VIH). La presente invención se refiere también a una composición farmacéutica que comprende el derivado de quinoleína y al proceso para prepararla como un nuevo compuesto intermedio.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305274.1A EP3059236A1 (en) | 2015-02-23 | 2015-02-23 | A new quinoline derivative for use in the treatment and prevention of viral infections |
| PCT/EP2016/053532 WO2016135052A1 (en) | 2015-02-23 | 2016-02-19 | A new quinoline derivative for use in the treatment and prevention of viral infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20170109A7 true CU20170109A7 (es) | 2018-02-08 |
| CU24525B1 CU24525B1 (es) | 2021-06-08 |
Family
ID=52629497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2017000109A CU24525B1 (es) | 2015-02-23 | 2016-02-19 | Derivado de quinoleína para tratar y prevenir infecciones virales |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10329317B2 (es) |
| EP (2) | EP3059236A1 (es) |
| JP (1) | JP6797126B2 (es) |
| KR (1) | KR102583506B1 (es) |
| CN (1) | CN107531681B (es) |
| AU (1) | AU2016223687B2 (es) |
| BR (1) | BR112017017500B1 (es) |
| CA (1) | CA2975577C (es) |
| CU (1) | CU24525B1 (es) |
| DK (1) | DK3262037T3 (es) |
| ES (1) | ES2785374T3 (es) |
| HR (1) | HRP20200649T1 (es) |
| HU (1) | HUE048577T2 (es) |
| LT (1) | LT3262037T (es) |
| MX (1) | MX381187B (es) |
| PL (1) | PL3262037T3 (es) |
| PT (1) | PT3262037T (es) |
| RS (1) | RS60369B1 (es) |
| RU (1) | RU2723013C2 (es) |
| SI (1) | SI3262037T1 (es) |
| WO (1) | WO2016135052A1 (es) |
| ZA (1) | ZA201705633B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| EP3059591A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | Methods for screening compounds for treating or preventing a viral infection or a virus-related condition |
| US20190034990A1 (en) * | 2017-07-26 | 2019-01-31 | International Business Machines Corporation | Information insight system for providers of products or services |
| EP3669874A1 (en) * | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of cancer |
| EP3669873A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
| EP3881844A1 (en) * | 2020-03-20 | 2021-09-22 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| US20230142547A1 (en) * | 2020-03-20 | 2023-05-11 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| EP3884946A1 (en) * | 2020-03-25 | 2021-09-29 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| US20240327388A1 (en) * | 2021-05-27 | 2024-10-03 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Quinolinamine compound, preparation method therefor and application thereof in pharmaceuticals |
| EP4201948A1 (en) | 2021-12-21 | 2023-06-28 | Abivax | Method of preparation of 1-(n-(quinolin-2-yl)-(phenylamino)-1-deoxy-beta-d-glucopyranuronic acid derivatives |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
| EP4215196A1 (en) * | 2022-01-24 | 2023-07-26 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor |
| TW202436295A (zh) * | 2022-11-25 | 2024-09-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 喹啉胺類化合物的可藥用鹽、晶型及其製備方法 |
| TW202436296A (zh) * | 2022-11-25 | 2024-09-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 喹啉胺類化合物晶型及其製備方法 |
| CN116617226B (zh) * | 2023-06-21 | 2024-06-25 | 湖北工业大学 | 新型吲哚喹啉衍生物作为肠道病毒71型抑制剂的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2436786A1 (fr) | 1978-09-21 | 1980-04-18 | Anvar | Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments |
| FR2627493B1 (fr) | 1988-02-23 | 1991-10-31 | Sanofi Sa | Procede de preparation de derives d'isoquinoleine |
| FR2645861A1 (fr) | 1989-04-17 | 1990-10-19 | Inst Nat Sante Rech Med | Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida |
| US5354853A (en) * | 1993-03-12 | 1994-10-11 | Genzyme Corporation | Phospholipid-saccharide conjugates |
| FR2859474B1 (fr) | 2003-09-04 | 2006-01-13 | Centre Nat Rech Scient | Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
| KR102016893B1 (ko) * | 2009-06-12 | 2019-08-30 | 아비박스 | 조기 노화, 구체적으로 조로증을 치료하는데 유용한 화합물 |
| EP2465502A1 (en) | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
| CN105530938B (zh) * | 2013-07-05 | 2019-10-22 | Abivax公司 | 用于治疗由逆转录病毒引起的疾病的化合物 |
| EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| EP2975034A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | A quinoline derivative for the treatment of inflammatory diseases and AIDS |
-
2015
- 2015-02-23 EP EP15305274.1A patent/EP3059236A1/en not_active Withdrawn
-
2016
- 2016-02-19 RU RU2017128643A patent/RU2723013C2/ru active
- 2016-02-19 RS RS20200447A patent/RS60369B1/sr unknown
- 2016-02-19 PT PT167055151T patent/PT3262037T/pt unknown
- 2016-02-19 PL PL16705515T patent/PL3262037T3/pl unknown
- 2016-02-19 BR BR112017017500-2A patent/BR112017017500B1/pt active IP Right Grant
- 2016-02-19 CU CU2017000109A patent/CU24525B1/es unknown
- 2016-02-19 DK DK16705515.1T patent/DK3262037T3/da active
- 2016-02-19 SI SI201630722T patent/SI3262037T1/sl unknown
- 2016-02-19 CA CA2975577A patent/CA2975577C/en active Active
- 2016-02-19 ES ES16705515T patent/ES2785374T3/es active Active
- 2016-02-19 JP JP2017543995A patent/JP6797126B2/ja active Active
- 2016-02-19 KR KR1020177023445A patent/KR102583506B1/ko active Active
- 2016-02-19 US US15/552,587 patent/US10329317B2/en active Active
- 2016-02-19 WO PCT/EP2016/053532 patent/WO2016135052A1/en active Application Filing
- 2016-02-19 MX MX2017010506A patent/MX381187B/es unknown
- 2016-02-19 HU HUE16705515A patent/HUE048577T2/hu unknown
- 2016-02-19 EP EP16705515.1A patent/EP3262037B1/en active Active
- 2016-02-19 LT LTEP16705515.1T patent/LT3262037T/lt unknown
- 2016-02-19 AU AU2016223687A patent/AU2016223687B2/en active Active
- 2016-02-19 CN CN201680011519.7A patent/CN107531681B/zh active Active
-
2017
- 2017-08-18 ZA ZA2017/05633A patent/ZA201705633B/en unknown
-
2020
- 2020-04-22 HR HRP20200649TT patent/HRP20200649T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20170109A7 (es) | Derivado de quinoleina para tratar y prevenir infecciones virales | |
| NZ732391A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| GT201700234A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
| CO2019010295A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP18073264A (es) | Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue | |
| CO2019013042A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| MX375170B (es) | Compuestos de amida para el tratamiento de vih. | |
| CO2018008421A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| NZ735575A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| UY37646A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CO2019012035A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112017005917A2 (pt) | processos e composições para indução de imunidade protetora contra infecção com o vírus da imunodeficiência humana | |
| DOP2018000035A (es) | Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| MX2017003928A (es) | Composiciones farmaceuticas de accion prolongada. | |
| BR112018002689A2 (pt) | composto, composição útil e método para tratamento de infecção por hiv | |
| UY37555A (es) | Derivados de ácido piridin-3-il-acético como inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| BR112018003181A2 (pt) | composto, composição, e, método para tratar infecção por hiv | |
| BR112018002678A2 (pt) | composto, composição, e, método para tratar infecção por hiv | |
| EA201990834A1 (ru) | Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний | |
| BR112018002681A2 (pt) | ?composto, composição, e, método para tratamento de infecção por hiv? | |
| EA033921B9 (ru) | Производные сиаловой кислоты и их применение в лечении инфекций, вызываемых вирусом гриппа |